Overview

Pharmacokinetics of Omadacycline in Cystic Fibrosis

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the pharmacokinetics of intravenous and oral omadacycline in patients with cystic fibrosis.
Phase:
Phase 4
Details
Lead Sponsor:
Paul Beringer
Collaborator:
Paratek Pharmaceuticals Inc